Chemical Chaperones Reduce Ionizing Radiation-induced Endoplasmic Reticulum Stress and Cell Death in IEC-6 Cells
Overview
Affiliations
Radiotherapy, which is one of the most effective approaches to the treatment of various cancers, plays an important role in malignant cell eradication in the pelvic area and abdomen. However, it also generates some degree of intestinal injury. Apoptosis in the intestinal epithelium is the primary pathological factor that initiates radiation-induced intestinal injury, but the mechanism by which ionizing radiation (IR) induces apoptosis in the intestinal epithelium is not clearly understood. Recently, IR has been shown to induce endoplasmic reticulum (ER) stress, thereby activating the unfolded protein response (UPR) signaling pathway in intestinal epithelial cells. However, the consequences of the IR-induced activation of the UPR signaling pathway on radiosensitivity in intestinal epithelial cells remain to be determined. In this study, we investigated the role of ER stress responses in IR-induced intestinal epithelial cell death. We show that chemical ER stress inducers, such as tunicamycin or thapsigargin, enhanced IR-induced caspase 3 activation and DNA fragmentation in intestinal epithelial cells. Knockdown of Xbp1 or Atf6 with small interfering RNA inhibited IR-induced caspase 3 activation. Treatment with chemical chaperones prevented ER stress and subsequent apoptosis in IR-exposed intestinal epithelial cells. Our results suggest a pro-apoptotic role of ER stress in IR-exposed intestinal epithelial cells. Furthermore, inhibiting ER stress may be an effective strategy to prevent IR-induced intestinal injury.
Chen O, Manig F, Lehmann L, Sorour N, Lock S, Yu Z Cell Mol Life Sci. 2020; 78(6):3021-3044.
PMID: 33230565 PMC: 8004506. DOI: 10.1007/s00018-020-03704-7.
Lipids in the tumor microenvironment: From cancer progression to treatment.
Corn K, Windham M, Rafat M Prog Lipid Res. 2020; 80:101055.
PMID: 32791170 PMC: 7674189. DOI: 10.1016/j.plipres.2020.101055.
Lee H, Kang S, Sonn J, Lim Y FEBS Open Bio. 2019; 9(9):1580-1588.
PMID: 31301124 PMC: 6722896. DOI: 10.1002/2211-5463.12699.
Lee E, Kim J, Lee H, Ryu J, Lee H, Sonn J Front Pharmacol. 2019; 10:417.
PMID: 31105565 PMC: 6492527. DOI: 10.3389/fphar.2019.00417.
Zheng X, Jin X, Li F, Liu X, Liu Y, Ye F Med Oncol. 2017; 34(2):25.
PMID: 28070729 DOI: 10.1007/s12032-017-0883-8.